# LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

> **NCT00680901** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 545 (actual)

## Conditions studied

- Neoplasms, Gastrointestinal Tract

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Placebo
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00680901
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-04
- **Primary completion:** 2012-09-24
- **Final completion:** 2024-10-03
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00680901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00680901, "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00680901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*